If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
210
results.
Updated on
21/02/2026 [06:51:00]
Results 100 to 125 of 210
Absstract of: US20260041783A1
The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and/or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.
Absstract of: US20260041769A1
The invention relates to agents and methods for targeted delivery of nucleic acids to cells. In some embodiments, the nucleic acid payload comprises a nucleic acid encoding an antigen receptor such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). The agents and methods for targeted delivery of a nucleic acid encoding an antigen receptor described herein may be used for generating in vitro/ex vivo or in vivo immune effector cells genetically modified to express an antigen receptor.
Absstract of: US20260041713A1
Disclosed herein are methods of enhancing skin regeneration, promoting wound healing (e.g., wherein the wound is a burn or actinic keratosis), and/or enhancing the topical delivery of active agents, the methods comprising the steps of applying a topical composition, comprising nanodiamond-zinc oxide core-shell particles, to the skin of a subject in need thereof.
Absstract of: US20260041643A1
The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Absstract of: WO2026035968A1
Provided herein are gene editing systems and compositions directed to effectuate in vivo edits in the AGT gene. Treatment or prevention of a disease, such as hypertension, through disruption of the production of angiotensinogen via genetic editing is disclosed herein. Disclosed are nickase-based gene editing systems designed to effectuate the installation of insertions and/or deletions (indel variants) and/or non-synonymous variants in the coding sequence of AGT. The nickase-based gene editing systems generally comprise one or more mRNAs that encode one or more nickases and a plurality of guide oligonucleotides (e.g., gRNAs) and may be delivered in vivo to a mammalian subject in need thereof via a suitable delivery system, such as lipid nanoparticles (LNPs) (with or without GalNAc targeting moieties) intravenously, or otherwise, administered to a patient as potentially a single-course or once-and-done therapeutic. The manufacturing, use, and formulation of the gene editing systems and compositions are also disclosed.
Absstract of: US20260041646A1
A thermally responsive nanosphere for binding to biofilms including a gold nanoparticle core functionalized with a polyethylene glycol; an R2ab fusion protein construct including an anchor that is a stable globular domain having a surface accessible cysteine residue, a linker, an S. epidermidis R2ab protein of SEQ ID NO. 1, and an elastin-like polypeptide. The linker may be a protein having SEQ ID NO. 7; and the anchor may be a modified third IgG binding domain from streptococcal protein G (GB3) having SEQ ID NO. 3, a ubiquitin protein having SEQ ID NO. 4, a Pin1 WW domain having SEQ ID NO. 5, and a fibronectin protein domain 3FN3 having SEQ ID NO. 6. A method for treating a biofilm containing S. epidermidis bacteria by binding a plurality of the nanospheres to the biofilm and exposing the biofilm to laser irradiation.
Absstract of: US20260041855A1
An electronic device includes a mouthpiece, a bladder, and a mesh assembly having a mesh material and a piezoelectric material. The mesh material is in contact with a liquid of the bladder. The mouthpiece, the bladder, and the mesh assembly are located in-line along a longitudinal axis of the device between opposite longitudinal ends of the device, with the mesh assembly extending between and separating the mouthpiece and the bladder. A liquid-filled cartridge also is disclosed for use with an electronic device for delivery of a substance into a body through respiration includes a liquid container; and a liquid contained within the container for aerosolizing and inhaling by a person using the electronic device. The liquid includes a plurality of nanoparticles in a nanoemulsion, the nanoparticles including the encapsulation of the substance to be delivered into the body through respiration. The nanoemulsion preferably is produced using a microfluidizing machine.
Absstract of: US20260041764A1
The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and/or immune modulator) and/or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and/or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.
Absstract of: US20260041759A1
A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and/or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N/mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.
Absstract of: WO2026035680A1
The present disclosure provides lipid nanoparticle compositions and methods of use. Among other things the present disclosure provides lipid nanoparticle compositions which increased specificity for specific cells or tissues. The present disclosure provides methods of use of the disclosed lipid nanoparticles.
Absstract of: WO2026035659A1
The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods thereof. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides.
Absstract of: US20260041750A1
The present invention relates to polygenic nucleic acid constructs comprising nucleotide sequences encoding Mycobacterium tuberculosis antigens and to mRNA vaccine constructs transcribed or obtained therefrom. Also provided are lipid nanoparticles including the mRNA vaccine constructs and vaccine compositions comprising the constructs described. The constructs, lipid nanoparticles containing them, and vaccine compositions described may be useful in methods for eliciting a protective immune response against Mycobacterium tuberculosis in a subject.
Absstract of: US20260041754A1
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject that, optionally, have reduced reactogenicity and promotes a local innate immune response in the subject while promoting an adaptive immune response. Compositions described herein include nanoparticles, optionally including an inorganic particle, capable of admixing with nucleic acids encoding proteins, antibodies, or immunomodulators. Methods of using the compositions as a therapeutic vaccine for the treatment of an infection or cancer are also provided.
Absstract of: US20260041670A1
The present disclosure discloses drugs for preventing and/or treating Alzheimer's disease (AD). A CF3CN derivative provided by present disclosure has any one of structural formulas 1-4 shown below. All four CF3CN derivatives have TrkB agonist activities; and specifically, the CF3CN derivative shown in formula 2 serves as an optimal derivative. In vivo PK studies reveal that the CF3CN derivative shown in the formula 2 is capable of improving a B/P Ratio of CF3CN, and overcoming the limitations of CF3CN. Nanoparticles are prepared by encapsulating the CF3CN derivatives with zein and lactoferrin, which may further enhance an oral bioavailability and a brain drug concentration, thereby improving AD treatment effects. By further improving the formulation and administration route, a liposome is employed to encapsulate the CF3CN derivative for both oral and intranasal administration, which effectively solves the problems of low bioavailability and low brain drug concentration of the derivative.
Absstract of: US20260041644A1
Disclosed are compositions, systems, and methods involving lipid nanoparticle primarily composed of phosphatidic acid (PA), monogalactosyldiacylglycerol (MGDG), and digalactosyldiacylglycerol (DGDG). In particular, the PA, MGDG, and DGDG are present in the nanoparticles in useful ratios, preferably falling in a ratio of 3 to 7, I to 3, and 2 to 4, respectively. Further, it is useful for the PA, MGDG, and DGDG to make up 90% or more of the total lipid in the nanoparticles. The disclosed lipid nanoparticles are useful as drug delivery systems for delivery of a drug, such as oral delivery, intravascular delivery, or intramuscular delivery. The disclosed lipid nanoparticles can be used in methods involving administration or delivery of the nanoparticles to a subject. In some forms, the subject can be a disease or condition, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, cancer, colon cancer, or a coronavirus infection.
Absstract of: US20260041645A1
The present invention relates to compositions and methods for delivery of therapeutic agent. In certain aspects, the invention comprises a metal-organic framework nanoparticle encapsulating a protein. In some aspects, the metal-organic framework nanoparticle encapsulating a protein is coated with an extracellular vesicle membrane.
Absstract of: WO2026033498A1
Disclosed herein are methods of increasing the potency of saRNA encapsulated lipid nanoparticles (LNPs) through a novel and surprisingly superior LNP manufacturing technique. The method disclosed herein overcomes technical difficulties and high costs associated with previous LNP manufacturing techniques. The methods disclosed herein, therefore, greatly improve the industrial production of LNPs in unexpected ways thereby providing more potent and less expensive LNPs for nucleic acid delivery.
Absstract of: WO2026033123A1
The present invention provides methods of encapsulating messenger RNA in lipid nanoparticles without the use of flammable solvents, and compositions produced by these methods, for mRNA delivery in therapeutic use. In particular, the present invention provides a process of encapsulating messenger RNA in lipid nanoparticles comprising a step of mixing (a) an mRNA solution comprising one or more mRNAs with (b) a lipid solution comprising one or more cationic lipids, one or more non-cationic lipids, one or more PEG-modified lipids, and a solvent, wherein the solvent comprises diethylene glycol monoethyl ether or tert-amyl alcohol, thereby forming mRNA encapsulated within the LNPs.
Absstract of: WO2026032777A1
The present invention relates to a method for obtaining nanodispersed systems comprising the steps of: a) mixing a compound C with a fluid A and obtaining a mixture in the form of a solution or dispersion; b) thermostatising the mixture obtained in step a) at a temperature of between -50 ºC and 200 ºC; c) adding a fluid B to the thermostatised mixture until a pressure P between 0 and 300 bar is attained obtaining the mixture AB; wherein molar fraction of fluid B is from 0.01 to 0.8; d) reducing the pressure of the mixture AB obtained in step c) to a pressure lower than or equal to 10 bar, by means of a valve, wherein said valve is heated during depressurization process to a temperature T in the range of 10 ºC to 50 ºC; and e) mixing fluid A with fluid E in which fluid A is miscible and compound C is partially or totally insoluble, controlling the flow rate and the temperature T of fluid A in the range of 10 ºC to 100 ºC.
Absstract of: US20260041647A1
Provided are compositions that include histone deacetylase (HDAC) inhibitors encapsulated in and/or otherwise associated with detectable nanoparticles, and methods for using the same in medical and veterinary applications including but not limited to treating diseases, disorders, and/or conditions associated with sensitivity to HDAC inhibitors; inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to HDAC inhibitors, and for treating inflammatory and/or an autoimmune diseases, disorders, and/or conditions associated with sensitivity to HDAC inhibitors. Also provided are methods for imaging cells, tissues, organs, and/or other targets in subject.
Absstract of: US20260041638A1
The invention relates to modified apolipoprotein with a targeting body. The targeting body may for example be an antibody or antigen binding fragment that allows targeting of e.g. a specific cell, tissue or organ. The modified apolipoprotein can be used as a carrier for a payload as such or when incorporated in a lipid nanoparticle. The modified apolipoprotein finds use in the treatment or prevention of diseases, or targeting a pay load to a specific target site.
Absstract of: US20260042787A1
The present invention belongs to the field of nanoporous materials, in particular metal organic frameworks (MOFs) and Lewis-based gas delivery and/or slow release, or the detection of Lewis-based gas(es) in gases or liquid streams.The present invention relates, inter alia, to a new ultra-microporous crystalline metal organic framework solid (comprising bisphosphonic acid ligands (also referred to as Phosphonate MOF), such as MIP-210(M) and uses thereof as a carrier in Lewis-based gas (such as NO) delivery. The invention also relates to controlled release of the Lewis-based gas in wounds, for example by topical application. The invention also encompasses a synthetic method for producing the new ultra-microporous crystalline metal organic framework solid of the invention.The MOFs of the present invention can be used in various applications such as gas carrier and/or for the controlled release of gas. The MOFs of the present invention thus are very versatile and have therapeutic and non therapeutic applications.
Absstract of: AU2024316257A1
Excipient granulations containing a viscosifying agent, a disintegrant, and one or more additional excipients are disclosed. An excipient granulation can be combined with a pharmaceutical granulation to provide a pharmaceutical composition. The excipient granulations can be used to increase the viscosity of an aqueous composition such as an oral pharmaceutical composition. When added to an aqueous solution, the excipient granulation can dissolve to provide a suspension of the pharmaceutical granules in a viscous solution. The excipient granulation can be used to improve the palatability of oral pharmaceutical compositions containing a pharmaceutical granulation.
Absstract of: WO2026033348A1
The invention relates to a process for the preparation of a composition comprising an oligosaccharide or a polysaccharide encapsulated in lipid nanoparticles, the process comprising the following steps: preparing a first solution of a lipid portion comprising a phospholipid, a neutral lipid, and a lipid sterol; preparing a second solution comprising a poly- or oligosaccharide; preparing a third solution containing a buffer; mixing the first and second solutions using a microfluidic system to obtain lipid nanoparticles encapsulating the oligosaccharide or the polysaccharide; combining the third solution with the first and second solutions. The invention also relates to a composition comprising lipid nanoparticles obtainable by the above-defined process, said composition comprising a lipid portion comprising a phospholipid, a neutral lipid compound in which a lipid chain is bound to a glycol group, and a lipid sterol; a buffer; and an oligosaccharide or polysaccharide.
Nº publicación: WO2026033411A1 12/02/2026
Applicant:
MOLECULES BIOLABS PRIVATE LTD [IN]
MOLECULES BIOLABS PRIVATE LIMITED
Absstract of: WO2026033411A1
The present invention discloses a formulation of bioactive liposomal gummies and a process of preparation thereof. The formulation comprises a bioactive component, an encapsulating agent, a sweetening agent, a flavoring agent, a gelling agent, an acidity regulator, a coloring agent, a bulking agent, a texturing agent, a thickening agent, a cross-linking polymer and water. The invention discloses a method of preparation of bioactive liposome using nano-milling process subsequently high-pressure homogenization, followed by a spray drying process. The process results in formulating dried bioactive liposomal gummies that exhibit increased stability and bioavailability of the liposomes making it a suitable for drug delivery system for wide range of bioactive agents. The bioactive liposomal gummies exhibit pH and temperature stability along with being palatable.
BOPI
Electronic site
